XML 57 R41.htm IDEA: XBRL DOCUMENT v3.22.0.1
Business Overview and Summary of Significant Accounting Policies - Narrative (Details)
12 Months Ended
Dec. 31, 2021
USD ($)
product
segment
Dec. 31, 2020
USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Number of products approved by the U.S. FDA | product 9  
Number of business segments | segment 1  
Provision for doubtful accounts $ 0 $ 0
Allowance for doubtful accounts receivable, current 0 0
Up-front and development milestone revenue recognized 42,500,000 $ 276,700,000
Deferred revenue $ 322,500,000  
Three individual customers | Customer concentration risk | Accounts receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Concentration risk, percentage 91.00% 93.00%
United States Government | Customer concentration risk | Accounts receivable    
New Accounting Pronouncements or Change in Accounting Principle [Line Items]    
Concentration risk, percentage 29.00%